Skip to Page Content

FREE PREVIEW | Subscribers get full access to this article:   Free Trial »   Subscribe »

The Pink Sheet Daily

FDA Stops Short Of Opiates Recall After Product Mix-Up At Novartis Plant


Executive Summary

The agency issued a public health advisory warning pharmacists and patients to inspect bottles of opiate products made at the plant, including Endo’s Percocet and Percodan, for improper pills; an FDA official says the risk-benefit analysis is different for Novartis OTC products, which were voluntarily recalled.


Purchase this Article

$50.00   Buy Now


For $50.00, purchase this 837-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Log In


Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.